JP2021527689A5 - - Google Patents
Info
- Publication number
- JP2021527689A5 JP2021527689A5 JP2020570911A JP2020570911A JP2021527689A5 JP 2021527689 A5 JP2021527689 A5 JP 2021527689A5 JP 2020570911 A JP2020570911 A JP 2020570911A JP 2020570911 A JP2020570911 A JP 2020570911A JP 2021527689 A5 JP2021527689 A5 JP 2021527689A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cells
- vector
- interleukin
- sequence
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688810P | 2018-06-22 | 2018-06-22 | |
| US62/688,810 | 2018-06-22 | ||
| PCT/US2019/038547 WO2019246563A1 (en) | 2018-06-22 | 2019-06-21 | Chimeric transmembrane proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527689A JP2021527689A (ja) | 2021-10-14 |
| JP2021527689A5 true JP2021527689A5 (https=) | 2022-06-21 |
| JPWO2019246563A5 JPWO2019246563A5 (https=) | 2022-06-21 |
Family
ID=67352580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570911A Pending JP2021527689A (ja) | 2018-06-22 | 2019-06-21 | キメラ膜貫通タンパク質及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11708401B2 (https=) |
| EP (1) | EP3810645A1 (https=) |
| JP (1) | JP2021527689A (https=) |
| KR (1) | KR20210025525A (https=) |
| CN (1) | CN112368298A (https=) |
| AU (2) | AU2019288733C1 (https=) |
| BR (1) | BR112020025804A2 (https=) |
| CA (1) | CA3102641A1 (https=) |
| IL (1) | IL279505A (https=) |
| MX (1) | MX2020013977A (https=) |
| SG (1) | SG11202011751WA (https=) |
| TW (1) | TWI809130B (https=) |
| WO (1) | WO2019246563A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201901642XA (en) * | 2016-08-26 | 2019-03-28 | Baylor College Medicine | Constitutively active cytokine receptors for cell therapy |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3688032B1 (en) | 2017-09-26 | 2025-11-05 | Cero Therapeutics Holdings, Inc. | Chimeric engulfment receptor molecules and methods of use |
| WO2019169290A1 (en) | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| JP7444781B2 (ja) | 2018-03-28 | 2024-03-06 | セロ・セラピューティクス・インコーポレイテッド | 細胞免疫療法組成物およびその使用 |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| BR112021017365A2 (pt) | 2019-03-01 | 2022-02-01 | Allogene Therapeutics Inc | Receptores de citocina quiméricos constitutivamente ativos |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| WO2020257823A2 (en) | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
| GB201911187D0 (en) | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| WO2021041806A1 (en) | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| US20210253696A1 (en) * | 2020-01-21 | 2021-08-19 | Cero Therapeutics, Inc. | Bivalent chimeric engulfment receptors and uses thereof |
| JP2023514407A (ja) | 2020-02-24 | 2023-04-05 | アロジーン セラピューティクス，インコーポレイテッド | 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞 |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| IL305571A (en) * | 2021-03-11 | 2023-10-01 | Kite Pharma Inc | Improving the function of immune system cells |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| KR20240022575A (ko) * | 2021-06-16 | 2024-02-20 | 센티 바이오사이언시스, 인코포레이티드 | 아머링된 키메라 수용체 및 이의 사용 방법 |
| WO2023276395A1 (ja) * | 2021-06-28 | 2023-01-05 | 愛知県 | キメラサイトカイン受容体 |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| CN118742561A (zh) * | 2022-04-11 | 2024-10-01 | 苏州沙砾生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN117683139A (zh) * | 2022-09-09 | 2024-03-12 | 信达细胞制药(苏州)有限公司 | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 |
| CN117402262A (zh) * | 2022-10-19 | 2024-01-16 | 上海君赛生物科技有限公司 | 基于lag3的嵌合免疫细胞辅助受体及其用途 |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| CN117402231B (zh) * | 2023-12-14 | 2024-04-09 | 南方医科大学南方医院 | 一种自发传递il-21信号的受体及其应用 |
| WO2026008700A1 (en) * | 2024-07-03 | 2026-01-08 | Immunofusion Bv | Il7r alpha signalling domain, chimeric antigen receptor and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| JP4124815B2 (ja) | 1991-10-31 | 2008-07-23 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | ＴＧＦ−β型受容体ｃＤＮＡおよびその用途 |
| CA2146973C (en) | 1992-10-29 | 2008-09-02 | Patricia R. Segarini | Uses of tgf-.beta. receptor fragment as a therapeutic agent |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US20030125251A1 (en) | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
| CA2451493C (en) | 2001-06-22 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Cell growth inhibitors containing anti-glypican 3 antibody |
| WO2004022597A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| US20060040354A1 (en) | 2004-07-20 | 2006-02-23 | O'keefe Theresa L | Novel polyadenylation signal for use in expression vectors |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CN102171247A (zh) * | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN107880136B (zh) | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| CN110563850A (zh) | 2012-04-30 | 2019-12-13 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
| SG11201407972RA (en) | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| NZ630790A (en) | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| PT2961831T (pt) | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| CN104140974B (zh) | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3126390B2 (en) | 2014-04-03 | 2026-01-07 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| US9926377B2 (en) | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
| US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| JP2017529851A (ja) | 2014-09-26 | 2017-10-12 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| US11382963B2 (en) | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN109414512A (zh) | 2016-04-22 | 2019-03-01 | 科济生物医药（上海）有限公司 | 用于细胞免疫疗法的组合物和方法 |
| CN105949324B (zh) | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| SG11201901642XA (en) * | 2016-08-26 | 2019-03-28 | Baylor College Medicine | Constitutively active cytokine receptors for cell therapy |
| CA3034691A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| BR112019013947A2 (pt) | 2017-01-10 | 2020-02-11 | Yamaguchi University | Anticorpo, receptor de antígeno quimérico, célula imunocompetente, gene de anticorpo, vetor, célula hospedeira, método para detectar gpc3, e, kit para a detecção de gpc3. |
| IL270138B2 (en) | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| CN111683962B (zh) | 2017-11-10 | 2025-05-16 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
| WO2019109980A1 (zh) | 2017-12-06 | 2019-06-13 | 科济生物医药（上海）有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
-
2019
- 2019-06-21 TW TW108121854A patent/TWI809130B/zh active
- 2019-06-21 BR BR112020025804-0A patent/BR112020025804A2/pt not_active IP Right Cessation
- 2019-06-21 SG SG11202011751WA patent/SG11202011751WA/en unknown
- 2019-06-21 KR KR1020207036743A patent/KR20210025525A/ko not_active Ceased
- 2019-06-21 AU AU2019288733A patent/AU2019288733C1/en active Active
- 2019-06-21 EP EP19742108.4A patent/EP3810645A1/en active Pending
- 2019-06-21 CN CN201980042055.XA patent/CN112368298A/zh active Pending
- 2019-06-21 JP JP2020570911A patent/JP2021527689A/ja active Pending
- 2019-06-21 US US16/449,089 patent/US11708401B2/en active Active
- 2019-06-21 CA CA3102641A patent/CA3102641A1/en active Pending
- 2019-06-21 MX MX2020013977A patent/MX2020013977A/es unknown
- 2019-06-21 WO PCT/US2019/038547 patent/WO2019246563A1/en not_active Ceased
-
2020
- 2020-12-16 IL IL279505A patent/IL279505A/en unknown
-
2023
- 2023-02-28 AU AU2023201197A patent/AU2023201197A1/en not_active Abandoned
- 2023-06-01 US US18/327,651 patent/US20230416339A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527689A5 (https=) | ||
| JPWO2019246563A5 (https=) | ||
| US20240059754A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| Ajina et al. | Strategies to address chimeric antigen receptor tonic signaling | |
| ES2909973T3 (es) | Receptores quiméricos para el antígeno que se dirigen a HER2 | |
| JP6961497B2 (ja) | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 | |
| EP3227339B1 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
| CN114656569B (zh) | 包含nkg2d结构域的多特异性嵌合受体和其使用方法 | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| CA3091681A1 (en) | Inducible chimeric cytokine receptors | |
| JP2018529376A5 (https=) | ||
| JP2024069352A5 (https=) | ||
| JP2020506700A5 (https=) | ||
| JP2021536265A5 (https=) | ||
| CN113621073A (zh) | 一种新型嵌合受体组合物、重组载体、细胞及其应用 | |
| US12187776B2 (en) | Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor | |
| WO2020259541A1 (zh) | 一种用于肿瘤治疗的嵌合抗原受体t淋巴细胞及其制备方法与应用 | |
| IL309653A (en) | Composition and methods for selective degradation of transgenic proteins | |
| US20250345429A1 (en) | Compositions and methods comprising chimeric adaptor polypeptides | |
| KR20230084470A (ko) | 면역 세포 기능의 향상 | |
| KR20230155521A (ko) | 면역 세포 기능의 향상 | |
| US20220325241A1 (en) | Immune effector cell for co-expressing chemokine receptor | |
| CN113402621A (zh) | 含有嵌合抗原受体的融合蛋白及其应用 | |
| CN112300288B (zh) | 一种cik细胞的嵌合抗原受体car及其应用 | |
| JPWO2023044456A5 (https=) |